Market News & Trends
XOMA Acquires Royalty & Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) & Phase 2 Oncology Asset
XOMA Corporation recently announced it has acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol, an oral therapeutic for Niemann-Pick…
ASLAN Pharmaceuticals Enters Strategic Licensing Deal With Zenyaku Kogyo for the Development & Commercialization of Eblasakimab
ASLAN Pharmaceuticals and Zenyaku Kogyo Co., Ltd., a subsidiary of privately held Zenyaku Holdings Co., Ltd. recently announced a strategic licensing agreement granting Zenyaku exclusive…
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
Eli Lilly and Company and DICE Therapeutics, Inc. recently announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company that leverages its proprietary….
Spaulding Clinical Expands Services to Include ADME Clinical Trials
Spaulding Clinical recently announced it is expanding its services to include ADME (absorption, distribution, metabolism, and excretion) clinical trials. This strategic addition further solidifies Spaulding…
Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic
The Lubrizol Corporation recently announced the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The license allows….
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement With GSK
SCYNEXIS, Inc. recently announced the achievement of a $25-million performance-based development milestone under its exclusive license agreement with GSK for….
Sygnature Discovery Launches its LPS In Vivo Model to Profile Early Stage Anti-Inflammatory Drugs
Sygnature Discovery has established an in vivo LPS model of inflammation that can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease,…
Mangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil-Based Mango-Flavored Rapid Dissolve ED Product
Mangoceuticals, Inc. recently announced the upcoming release of its second Mango ED product leveraging the company’s existing custom compound alongside Sildenafil, which is the active…
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded US Patent
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) has issued US Patent No. 16/825,371 titled Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis,…
Croda Announces Two New Partnerships to Drive Sustainable Delivery Systems for the Pharmaceutical Industry
Croda International Plc recently announced it has signed two new partnership agreements that will help the pharmaceutical industry move toward a more sustainable supply chain for vaccine adjuvants…..
NodThera Announces Positive First-in-Human Data for Two Brain Penetrant NLRP3 Inflammasome Inhibitors
NodThera recently announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796, and provides an update on the company’s priority clinical…
Ashland Announces Multifunctional Disintegrant for Improved Pharmaceutical Process Throughput
Ashland is introducing Polyplasdone Plus, a co-processed multifunctional direct compression superdisintegrant containing a glidant and lubricant. Saving time and simplifying development, the multifunctional disintegrant offers…
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV & hMPV in Older Adults
Icosavax, Inc. recently announced the initiation of a Phase 2 clinical trial of IVX-A12, a combination bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)…
Curia Expands Cell Line Development Offering With CHOZN Platform
Curia signs license agreement with MilliporeSigma to support production of proteins and antibodies….
Thaerapy BV & Resyca BV Announce Exclusive License Agreement for Soft Mist Inhaler Technology
Thaerapy BV and Resyca BV a joint venture of Medspray Pharma BV and Recipharm AB, a leader in the development of soft mist inhalers, recently announced today the signing of an exclusive license agreement for Resyca’s soft mist….
Celanese & Nanoform Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants
Celanese and Nanoform Finland Plc recently provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery…..
ANAVEX2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients With Rett Syndrome
Anavex Life Sciences Corp. recently announced the first patients with Rett syndrome from the ANAVEX2-73-RS-003 study (EXCELLENCE) are able to continue treatment with ANAVEX2-73 (blarcamesine)…
Helocyte Announces $3.22-Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (CMV) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients….
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b Trial of Rencofilstat
Hepion Pharmaceuticals, Inc. recently announced the Data and Safety Monitoring Board (DSMB) has met to review the current data for the ASCEND-NASH Phase 2b trial…
Ventyx Biosciences Announces Initiation of Dosing in Phase 1 Trial of Novel CNS-Penetrant NLRP3 Inhibitor
Ventyx Biosciences, Inc. recently announced the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system (CNS)-penetrant NLRP3…
